Cytosorbents (CTSO) Liabilities and Shareholders Equity (2010 - 2026)

Cytosorbents has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $40.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 20.12% year-over-year to $40.6 million; the trailing twelve-month figure through Mar 2026 stood at $178.5 million (down 10.48% YoY), and the FY2025 full-year result was $44.2 million, down 6.73% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $40.6 million, down from $44.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $83.3 million in Q1 2022, with the low at $40.6 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $53.8 million across 5 years, with a median of $50.8 million in 2025.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slumped 34.5% — and 2025, when it gained 7.88%.
• Cytosorbents' Liabilities and Shareholders Equity stood at $63.2 million in 2022, then slipped by 16.25% to $53.0 million in 2023, then dropped by 10.55% to $47.4 million in 2024, then fell by 6.73% to $44.2 million in 2025, then decreased by 8.19% to $40.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $40.6 million (Q1 2026), $44.2 million (Q4 2025), and $45.8 million (Q3 2025), per Business Quant data.